Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates by Carolyn Helms | Jul 26, 2017 | Portfolio News
Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters’ Option by Carolyn Helms | Jul 25, 2017 | Portfolio News
Kala Pharmaceuticals Announces Pricing of Initial Public Offering by Carolyn Helms | Jul 20, 2017 | Portfolio News
Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of Directors by Carolyn Helms | Jul 19, 2017 | Portfolio News
Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters by Carolyn Helms | Jul 6, 2017 | Portfolio News
